Entering text into the input field will update the search result below

Dyax boosted by Lilly Ramucirumab data

Feb. 19, 2014 10:40 AM ETDyax Corp. (DYAX) StockDYAXBy: Stephen Alpher, SA News Editor
  • Reiterating his Buy rating and $13 price target on Dyax (DYAX +2.2%), Needham's Serge Belanger says "Ramucirumab is one of Dyax's LFRP programs for which Dyax would receive 2%-3% sales royalties. We await more detailed data from the REVEL study to update our model."
  • Earlier: Eli Lilly's Phase III study meets its primary endpoint.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
DYAX--
Dyax Corp.